Genmab — April 2021
-
not a fan of Zacks, but anyway; The Zacks Consensus Estimate for Imbruvica, Darzalex and Stelara is pegged at $1.2 billion, $1.22 billion and $2.18 billion, respectively. https://www.nasdaq.com/articles/will-jj-jnj-kickstart-pharma-q1-earnings-with-a-beat-2021-04-15
-
The Lancet - Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials https://www.thelancet.com/journals/landia/article/PIIS2213-8587(21)00056-5/fulltext
-
Bare fordi, der er nogen efter en, kan man godt være paranoid
-
2021 "inflection point" for Genmab, says chief executive https://www.thepharmaletter.com/article/2021-inflection-point-for-genmab-says-chief-executive
-
Genmab analyse - Kursmål 2025: https://www.proinvestor.com/boards/92843#92845
-
-
Jesper Lund er en skarp analytiker som ikke gør tingene sværere end de er. Han har selv haft Genmab i mange år.
-
Har han skrevet hvilke midler en RG på 37,5 er baseret på?
-
Plimsoller..Jesper bor fast i Vietnam. Han er vist på stranden lige nu. Jeg sender ham lige en besked og dit spørgsmål.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind